1
Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia
Condition(s): Plasma Cell Leukemia; Multiple Myeloma Last Updated: September 21, 2011Recruiting
670 Clinical Trials for: Bortezomib, Page 1 of 34
Hide Studies Not Seeking New Volunteers
2
Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone
Condition(s): Prostate Cancer Last Updated: August 17, 2012Active, not recruiting
3
Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease
Condition(s): Graft-versus-Host Disease Last Updated: May 8, 2013Completed
4
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Condition(s): Lymphoma Last Updated: January 2, 2013Active, not recruiting
5
Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma
Condition(s): Multiple Myeloma Last Updated: October 29, 2012Completed
6
An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)
Condition(s): Multiple Myeloma; Non-Hodgkin's Lymphoma Last Updated: January 26, 2012Completed
7
Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
Condition(s): Multiple Myeloma Last Updated: April 5, 2013Active, not recruiting
8
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
Condition(s): Waldenstrom's Macroglobulinemia Last Updated: March 15, 2013Active, not recruiting
9
Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens
Condition(s): Multiple Myeloma Last Updated: February 12, 2013Recruiting
10
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Condition(s): Multiple Myeloma Last Updated: December 20, 2007Active, not recruiting
11
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome
Condition(s): Acute Lymphocytic Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome; Chronic Myelogenous Leukemia Last Updated: April 26, 2013Recruiting
12
A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma
Condition(s): Multiple Myeloma Last Updated: March 28, 2013Completed
13
Study of Vorinostat (MK-0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma (MK-0683-088 AMN)
Condition(s): Multiple Myeloma Last Updated: May 9, 2013Active, not recruiting
14
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Condition(s): Waldenstrom's Macroglobulinemia Last Updated: February 1, 2013Recruiting
15
Randomized Phase 3b Study in Previously Untreated Multiple Myeloma Patients: VELCADE,Thalidomide, and Dexamethasone Versus VELCADE and Dexamethasone Versus VELCADE, Melphalan, and Prednisone
Condition(s): Multiple Myeloma Last Updated: January 23, 2013Active, not recruiting
16
Bortezomib (Velcade) Plus Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma
Condition(s): Mantle Cell Lymphoma; Lymphoma Last Updated: February 14, 2013Recruiting
17
Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer
Condition(s): Non Small Cell Lung Cancer Last Updated: January 8, 2013Suspended
18
Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease
Condition(s): Chronic Graft Versus Host Disease Last Updated: January 28, 2013Completed
19
Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML
Condition(s): Acute Myelogenous Leukemia Last Updated: September 28, 2010Completed
20
Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma
Condition(s): Hodgkin Lymphoma; Lymphoma Last Updated: July 5, 2012Completed
